Cargando…
Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to com...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626385/ https://www.ncbi.nlm.nih.gov/pubmed/29026298 http://dx.doi.org/10.2147/IJN.S147738 |
_version_ | 1783268535836868608 |
---|---|
author | Helmy, Hebatullah Samy El-Sahar, Ayman E Sayed, Rabab H Shamma, Rehab Nabil Salama, Alaa Hamed Elbaz, Eman Maher |
author_facet | Helmy, Hebatullah Samy El-Sahar, Ayman E Sayed, Rabab H Shamma, Rehab Nabil Salama, Alaa Hamed Elbaz, Eman Maher |
author_sort | Helmy, Hebatullah Samy |
collection | PubMed |
description | BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to compare the therapeutic efficacy of systemic administration of lornoxicam-loaded nanomicellar formula (LX-NM) with that of free LX. MATERIALS AND METHODS: The LX-loaded mixed polymeric nanomicellar formula was prepared by direct equilibrium technique. Two rat models were used in the study: carrageenan-induced acute edema and Freund’s complete adjuvant (FCA)-induced chronic arthritis. RESULTS: The inhibitory effect of LX-NM on carrageenan-induced edema was higher than free LX for the same dose (1.3 mg/kg, i.p.). LX-NM (0.325 mg/kg, i.p.) produced effects comparable to that of diclofenac, which served as a standard. In the FCA model, daily treatment with LX-NM (0.325 mg/kg, i.p.) starting on day 14 significantly reduced the percentage of edema and increased weight growth. However, the same dose of LX failed to confer any significant change. Additionally, LX-NM significantly attenuated the rise of tumor necrosis factor-α (TNF-α), interleukin-1β, prostaglandin E2, nuclear factor-κβ, malondialdehyde and nitric oxide serum levels. In contrast, LX failed to show any significant reduction in elevated serum biomarkers except for TNF-α. CONCLUSION: LX-NM is an alternative delivery system that is simply prepared at low costs. It showed a superior therapeutic efficacy against RA compared to free LX. Thus, LX-NM can be considered as a promising candidate for treatment of RA and similar inflammatory disorders. |
format | Online Article Text |
id | pubmed-5626385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56263852017-10-12 Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis Helmy, Hebatullah Samy El-Sahar, Ayman E Sayed, Rabab H Shamma, Rehab Nabil Salama, Alaa Hamed Elbaz, Eman Maher Int J Nanomedicine Original Research BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory disease treated by nonsteroidal anti-inflammatory drugs (NSAIDs) including lornoxicam (LX). Nanocarriers have been used to increase the efficacy and reduce the side effects of various drugs. The objective of the present study was to compare the therapeutic efficacy of systemic administration of lornoxicam-loaded nanomicellar formula (LX-NM) with that of free LX. MATERIALS AND METHODS: The LX-loaded mixed polymeric nanomicellar formula was prepared by direct equilibrium technique. Two rat models were used in the study: carrageenan-induced acute edema and Freund’s complete adjuvant (FCA)-induced chronic arthritis. RESULTS: The inhibitory effect of LX-NM on carrageenan-induced edema was higher than free LX for the same dose (1.3 mg/kg, i.p.). LX-NM (0.325 mg/kg, i.p.) produced effects comparable to that of diclofenac, which served as a standard. In the FCA model, daily treatment with LX-NM (0.325 mg/kg, i.p.) starting on day 14 significantly reduced the percentage of edema and increased weight growth. However, the same dose of LX failed to confer any significant change. Additionally, LX-NM significantly attenuated the rise of tumor necrosis factor-α (TNF-α), interleukin-1β, prostaglandin E2, nuclear factor-κβ, malondialdehyde and nitric oxide serum levels. In contrast, LX failed to show any significant reduction in elevated serum biomarkers except for TNF-α. CONCLUSION: LX-NM is an alternative delivery system that is simply prepared at low costs. It showed a superior therapeutic efficacy against RA compared to free LX. Thus, LX-NM can be considered as a promising candidate for treatment of RA and similar inflammatory disorders. Dove Medical Press 2017-09-22 /pmc/articles/PMC5626385/ /pubmed/29026298 http://dx.doi.org/10.2147/IJN.S147738 Text en © 2017 Helmy et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Helmy, Hebatullah Samy El-Sahar, Ayman E Sayed, Rabab H Shamma, Rehab Nabil Salama, Alaa Hamed Elbaz, Eman Maher Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title | Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title_full | Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title_fullStr | Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title_full_unstemmed | Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title_short | Therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
title_sort | therapeutic effects of lornoxicam-loaded nanomicellar formula in experimental models of rheumatoid arthritis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5626385/ https://www.ncbi.nlm.nih.gov/pubmed/29026298 http://dx.doi.org/10.2147/IJN.S147738 |
work_keys_str_mv | AT helmyhebatullahsamy therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis AT elsaharaymane therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis AT sayedrababh therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis AT shammarehabnabil therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis AT salamaalaahamed therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis AT elbazemanmaher therapeuticeffectsoflornoxicamloadednanomicellarformulainexperimentalmodelsofrheumatoidarthritis |